Oscar Health is projected to report Q2 2026 revenue of $4.93 billion and EPS of $0.43, while the stock currently trades at $31.07 against an average analyst target of $24.20.
Investors are primarily focused on the Medical Loss Ratio (MLR) and its impact on the company's trajectory toward sustainable full-year profitability.
Following a record Q1 profit, the market is watching whether Oscar can manage seasonal medical utilization and risk adjustment transfer (RAT) dynamics. Maintaining its expanded membership base, which management expects to track at 3.0 million paid members for Q2 2026, remains critical to achieving its ambitious 2026 margin targets.